| UHC Commercial Medical & Drug | Testosterone Replacement or Supplementation Therapy – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Transarterial Radioembolization (TARE)/ Selective Internal Radiation Therapy (SIRT) for the Treatment of Malignant Cancers of the Liver – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Vagus and External Trigeminal Nerve Stimulation – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Video Electroencephalographic (vEEG) Monitoring and Recording – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Virtual Upper Gastrointestinal Endoscopy – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Visual Information Processing Evaluation and Orthoptic and Vision Therapy – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Vyjuvek® (Beramagene Geperpavec-Svdt) – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Xiaflex® (Collagenase Clostridium Histolyticum) – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| Ambetter Health Alabama Clinical | Concert Genetic Testing: Multisystem Genetic Conditions (V2.2025) | 2026-01-01 |
| Ambetter Health Georgia Clinical | Concert Genetic Testing: Multisystem Genetic Conditions | 2026-01-01 |